PMID- 38371257
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240220
IS  - 2222-3959 (Print)
IS  - 2227-4898 (Electronic)
IS  - 2222-3959 (Linking)
VI  - 17
IP  - 2
DP  - 2024
TI  - Effect of aflibercept combined with triamcinolone acetonide on aqueous humor 
      growth factor and inflammatory mediators in diabetic macular edema.
PG  - 297-303
LID - 10.18240/ijo.2024.02.11 [doi]
AB  - AIM: To investigate the efficacy of aflibercept combined with sub-tenon injection 
      of triamcinolone acetonide (TA) in treating diabetic macular edema (DME) and to 
      examine changes in growth factors and inflammatory mediator levels in aqueous 
      humor after injection. METHODS: Totally 67 DME patients (67 eyes) and 30 cataract 
      patients (32 eyes) were enrolled as the DME group and the control group, 
      respectively. The DME group was divided into the aflibercept group (34 cases) and 
      the aflibercept combined with TA group (combined group, 33 cases). The aqueous 
      humor of both groups was collected during the study period. The aqueous levels of 
      vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 
      (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-1beta (IL-1beta) 
      were detected using a microsphere suspension array technology (Luminex 200TM). 
      Aqueous cytokines, best-corrected visual acuity (BCVA), central macular thickness 
      (CMT), and complications before and after treatment were compared between the 
      aflibercept group and combined group. RESULTS: The concentrations of VEGF, MCP-1, 
      IL-6, and IL-8 in the aqueous humor were significantly higher in the DME group 
      than those of the control group (all P<0.01). After 1mo of surgery, the 
      concentrations of VEGF, MCP-1, IL-6, and IL-8 in the aqueous humor were 
      significantly lower in the combined group than those of the aflibercept group 
      (all P<0.01). The BCVA and CMT values of the two groups were statistically 
      different after 1 and 2mo of treatment (P<0.01). However, the difference was not 
      statistically significant after 3mo of treatment (P>0.05). CONCLUSION: The 
      cytokines VEGF, MCP-1, IL-6, and IL-8 in the aqueous humor of DME patients are 
      significantly increased. Aflibercept and aflibercept combined with TA have good 
      efficacy in DME patients, can effectively reduce CMT, improve the patient's 
      vision, and have high safety. Aflibercept combined with TA can quickly 
      down-regulate the aqueous humor cytokines and help to relieve macular edema 
      rapidly. However, the long-term efficacy is comparable to that of aflibercept 
      alone.
CI  - International Journal of Ophthalmology Press.
FAU - Li, De-Shuang
AU  - Li DS
AD  - Shenzhen Aier Eye Hospital, Aier Eye Hospital, Jinan University, Shenzhen 518031, 
      Guangdong Province, China.
FAU - Liao, Hong-Xia
AU  - Liao HX
AD  - Shenzhen Aier Eye Hospital, Aier Eye Hospital, Jinan University, Shenzhen 518031, 
      Guangdong Province, China.
FAU - Zhang, Jing-Lin
AU  - Zhang JL
AD  - Guangzhou Aier Eye Hospital, Jinan University, Guangzhou 510040, Guangdong 
      Province, China.
FAU - Qin, Bo
AU  - Qin B
AD  - Shenzhen Aier Eye Hospital, Aier Eye Hospital, Jinan University, Shenzhen 518031, 
      Guangdong Province, China.
LA  - eng
PT  - Journal Article
DEP - 20240218
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC10827616
OTO - NOTNLM
OT  - aflibercept
OT  - aqueous humor
OT  - cytokines
OT  - diabetic macular edema
OT  - triamcinolone acetonide
COIS- Conflicts of Interest: Li DS, None; Liao HX, None; Zhang JL, None; Qin B, None.
EDAT- 2024/02/19 06:43
MHDA- 2024/02/19 06:44
PMCR- 2024/02/18
CRDT- 2024/02/19 04:22
PHST- 2023/10/19 00:00 [received]
PHST- 2023/11/28 00:00 [accepted]
PHST- 2024/02/19 06:44 [medline]
PHST- 2024/02/19 06:43 [pubmed]
PHST- 2024/02/19 04:22 [entrez]
PHST- 2024/02/18 00:00 [pmc-release]
AID - ijo-17-02-297 [pii]
AID - 10.18240/ijo.2024.02.11 [doi]
PST - epublish
SO  - Int J Ophthalmol. 2024 Feb 18;17(2):297-303. doi: 10.18240/ijo.2024.02.11. 
      eCollection 2024.